Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study

BACKGROUND: Grade 3 neuroendocrine neoplasms (NENs) of gastroenteropancreatic (GEP) origin with Ki-67 indices <55% do not respond well to platinum-based chemotherapy. The combination of capecitabine and temozolomide (CAPTEM) has shown favorable responses in grade 1-2 NENs, but has rarely been stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeong, H., Shin, J., Jeong, J.H., Kim, K.-p., Hong, S.-M., Kim, Y.-i., Ryu, J.-S., Ryoo, B.-Y., Yoo, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099746/
https://www.ncbi.nlm.nih.gov/pubmed/33901869
http://dx.doi.org/10.1016/j.esmoop.2021.100119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099746/
https://www.ncbi.nlm.nih.gov/pubmed/33901869
http://dx.doi.org/10.1016/j.esmoop.2021.100119

Ejemplares similares